Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

7 2.49

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.53

Max

7.03

Belangrijke statistieken

By Trading Economics

Inkomsten

80M

-22M

Verkoop

987K

35M

EPS

-1.24

Winstmarge

-63.857

Werknemers

228

EBITDA

8M

-9.8M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-19.12% downside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-38M

161M

Vorige openingsprijs

4.51

Vorige sluitingsprijs

7

Nieuwssentiment

By Acuity

50%

50%

162 / 340 Rangschikking in Healthcare

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 jul 2026, 23:41 UTC

Social Media
Event
News

Karyopharm Therapeutics shares fell sharply after its Phase 3 trial for selinexor failed to meet key endpoints, leading to a shift in focus away from endometrial cancer.

29 jul 2026, 19:27 UTC

Macro Event

Karyopharm Therapeutics shares are lower as investor anxiety rises following the Federal Reserve's decision to maintain interest rates amid global uncertainties.

27 jul 2026, 19:07 UTC

Karyopharm Therapeutics Inc shares are lower during Monday's trading session, reflecting ongoing weakness and broader market trends amid declining crude oil prices.

24 jul 2026, 19:42 UTC

Karyopharm Therapeutics Inc. shares are higher during Friday's session, continuing a notable advance since Thursday, despite broader market challenges.

23 jul 2026, 09:01 UTC

Karyopharm Therapeutics Inc shares are higher in pre-market trading, continuing an upward trend since Wednesday, despite recent volatility and no specific news.

22 jul 2026, 18:41 UTC

Social Media

Karyopharm Therapeutics shares are declining amid market caution and rising crude oil prices. RBC Capital reaffirmed its Outperform rating with a $16 price target.

21 jul 2026, 20:12 UTC

Karyopharm Therapeutics shares are lower in after-market hours, with no specific news driving the decline despite positive sentiment in U.S. markets.

20 jul 2026, 23:01 UTC

News

Karyopharm Therapeutics shares fell in after-market hours following the announcement of a leadership cash retention program aimed at key executives.

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

-19.12% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.67 USD  -19.12%

Hoogste 7 USD

Laagste 3 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Sentiment

By Acuity

162 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

help-icon Live chat